Announcement on the Company's 2019 Daily Related Transactions
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2019-011
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于公司2019年度日常关联交易的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 浙江尖峰集团股份有限公司及控股子公司(以下简称“本公司”)预计 2019 年与本公司联营企业天士力控股集团有限公司及其控股子公司(以下简称“天士力集团”)发生采购、销售等日常关联交易,交易金额合计预计不超过人民币2290万元。
l 本次日常关联交易系本集团日常经营业务中发生的持续性关联交易,遵守“公平、公正、公开”的市场交易原则,不会影响公司独立性,不会对公司的财务状况、经营成果产生不利影响,不会损害本公司或中小股东的利益。
一、日常关联交易基本情况
(一)日常关联交易履行的审议程序
根据公司经营需要,2019年本公司预计与天士力集团发生采购、销售等日常关联交易,上述日常关联交易合计发生额度在本公司2018年底经审计净资产的0.5%到5%之间,根据上海证券交易《股票上市规则》及公司《章程》的规定,该关联交易事项需提交董事会审议,但不需提交股东大会审议。
2019年4月26日,公司召开了第十届董事会第10次会议,公司现有九名董事,其中八名董事亲自参加了会议,杜自弘董事委托蒋晓萌董事代为出席会议并表决,根据《上海证券交易所股票上市规则》的规定,本公司董事会就上述议案进行表决时,关联董事蒋晓萌先生、虞建红先生、杜自弘先生回避了该议案的表决。经审议与表决,董事会以6票同意、0票反对、0票弃权审议通过了《关于公司2019年度日常关联交易的议案》。
公司独立董事事前对该事项进行了审议,同意将该议案提交给公司第十届董事会第10次会议审议,并对董事会通过该议案发表了同意的独立意见,认为:该项关联交易遵守“公平、公正、公开”的市场交易原则,以招标价或以医疗机构中标价为基准协商确定交易价格,交易金额占公司总销售、采购的比例较小,不会影响本公司独立性,不会对本公司的财务状况、经营成果产生不利影响,未发现有损害公司及中小股东权益的情形。同意公司2019年度相关日常关联交易事项。
(二)预计日常关联交易金额 单位:万元
|
交易内容 |
2019年预计金额 |
2019年已发生额 |
2018年发生额(不含税) |
占总销售、采购金额的比例(%) |
|
向关联人购买商品 |
1550.00 |
90.95 |
712.64 |
0.36 |
|
向关联人销售商品 |
740.00 |
193.68 |
542.88 |
0.16 |
|
合计 |
2290.00 |
284.63 |
1255.52 |
|
二、关联方介绍和关联关系
(一)关联方的基本情况。
天士力控股集团有限公司,成立于2000年3月30日,公司住所为天津北辰科技园区,法定代表人为闫希军,公司注册资本为34358.90万元人民币。公司经营范围:对外投资、控股;天然植物药种植及相关加工、分离;组织所属企业开展产品的生产、科研、销售、进出口经营业务;各类商品、物资的批发、零售;技术开发、咨询、服务、转让生物技术(不含药品生产与销售)及产品;自有设备、房屋的租赁;各类经济信息咨询;本企业研制开发的技术和生产的科研产品的出口业务;本企业科研和生产所需的技术、原辅材料、机械设备、仪器仪表、零配件的进口业务;本企业的进料加工和“三来一补”业务;矿业开发经营;原料药(盐酸非索非那定、右佐匹克隆)生产;因特网信息服务(除新闻、出版、教育、医疗器械和电子公告以外的信息服务内容,业务覆盖范围:天津市);会议及展览服务;游览景区管理;旅游管理服务;旅游信息咨询服务;门票销售与讲解服务;旅游商品、纪念品开发与销售。(以上经营范围内国家有专营专项规定的按规定办理)。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
截至2018年12月31日该公司总资产409.46亿元,归属于母公司股东净资产54.50亿元,2018年实现营业收入197.97亿元,归属于母公司股东净利润2.92亿元。
(二)与上市公司的关联关系
本公司持有天士力集团20.76%的股权,且本公司董事蒋晓萌先生、虞建红先生兼任天士力集团的董事,本公司董事杜自弘先生曾担任天士力集团的董事(卸任未满12个月),根据《上海证券交易所股票上市规则》及其他相关规定,天士力集团及其控股子公司为本公司的关联人,本项交易为关联交易。
|
关联方名称 |
关联关系 |
|
天士力控股集团有限公司 |
本公司董事兼任该公司董事 |
|
天津天士力现代中药资源有限公司 |
天士力集团控制的下属公司,与天士力集团共同构成同一关联人。 |
|
重庆国清中药材有限公司 |
|
|
江苏天士力帝益药业有限公司 |
|
|
天津天士力医药商业有限公司 |
|
|
辽宁天士力医药有限公司 |
|
|
陕西天士力医药有限公司 |
|
|
天士力(佛山)医药有限公司 |
|
|
天士力(汕头)医药有限公司 |
(三)前期同类关联交易的执行情况和履约能力分析
2018年,公司与天士力集团之间发生的关联交易总额为1255.52万元(不含税),其中:采购商品712.64万元,占公司采购金额的0.36%;销售商品542.88万元,占公司销售的0.16%。该交易占同类交易金额的比例很小,不影响本公司的独立性。各关联方均依法存续且生产经营正常,经济效益和财务状况良好,履约能力强,不会给交易双方的交易行为带来风险。
三、关联交易主要内容和定价政策
(一)关联交易主要内容
本公司拟在2019年度继续向天士力集团采购复方丹参滴丸、养血清脑丸、水飞蓟宾胶囊、替莫唑胺胶囊、右佐匹克隆片等产品,并继续向其销售力斯得、帕罗西汀、玻璃酸钠滴眼液、醋氯芬酸缓释片、注射用盐酸头孢甲肟、延胡索、生半夏等产品。
(二)定价政策
公司与关联方的交易本着公平、公正、公开的市场交易原则,交易价格主要以招标价或以医疗机构中标价为基准协商确定。
四、关联交易目的和对上市公司的影响
本次关联交易系本公司日常经营业务中发生的持续性关联交易,有利于发挥双方的产品优势和销售、采购的网络优势,实现优势互补和资源合理配置,提升营销能力,增加销售收入。同时,天士力集团为本公司的联营企业,本公司持有其20.76%的股权,该公司及其控股子公司的收入增加、效益提升有利于本公司的业绩增长。
上述交易遵守“公平、公正、公开”的市场交易原则,以招标价或以医疗机构中标价为基准协商确定交易价格,交易金额占销售、采购的比例较小,不会影响本公司独立性,不会对本公司的财务状况、经营成果产生不利影响,不会损害本公司或中小股东的利益。
特此公告
l 报备文件
(一)公司第十届董事会第10次会议决议;
(二)第九届监事会第6次会议决议;
(三)独立董事的独立意见
(四)独立董事关于公司关联交易事前认可声明
特此公告。
浙江尖峰集团股份有限公司
董事会
二〇一九年四月三十日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05